<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00070473</url>
  </required_header>
  <id_info>
    <org_study_id>ADVL0311</org_study_id>
    <secondary_id>NCI-04-C-0261</secondary_id>
    <secondary_id>CDR0000334572</secondary_id>
    <secondary_id>COG-ADVL0311</secondary_id>
    <nct_id>NCT00070473</nct_id>
  </id_info>
  <brief_title>Pemetrexed Disodium in Treating Young Patients With Recurrent Solid Tumors</brief_title>
  <official_title>A Phase I Study of Pemetrexed (LY231514, Alimta) in Children and Adolescents With Recurrent Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium, use different ways to&#xD;
      stop tumor cells from dividing so they stop growing or die. Pemetrexed disodium may stop the&#xD;
      growth of tumor cells by blocking the enzymes necessary for their growth.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of pemetrexed disodium&#xD;
      in treating young patients with recurrent solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of pemetrexed disodium in children and adolescents&#xD;
           with refractory solid tumors.&#xD;
&#xD;
        -  Determine the dose-limiting toxic effects of this drug in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine, preliminarily, the antitumor activity of this drug in these patients.&#xD;
&#xD;
        -  Correlate the presence of the C677T polymorphism of the methylenetetrahydrolate&#xD;
           reductase gene, the presence of a polymorphism in the enhancer region of the thymidylate&#xD;
           synthase (TS) gene promoter (2R and 3R tandem repeats), the presence of a polymorphism&#xD;
           within one of those repeats, and the presence of a functional polymorphism in the&#xD;
           3'-untranslated region with toxicity in patients treated with this drug.&#xD;
&#xD;
        -  Correlate homocysteine and methylmalonic acid levels at study entry with toxicity in&#xD;
           patients treated with this drug.&#xD;
&#xD;
        -  Correlate various gene expression profiles with response in patients treated with this&#xD;
           drug.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21&#xD;
      days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of pemetrexed disodium until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2&#xD;
      of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-36 patients will be accrued for this study within 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Event Free Survival</measure>
    <time_frame>Length of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose Limiting Toxicity</measure>
    <time_frame>Length of study</time_frame>
    <description>Any patient who experiences DLT at any time during protocol therapy will be considered evaluable for toxicity. Patients not experiencing DLT must complete a full cycle of therapy to be considered potentially evaluable for toxicity. Patients who are not evaluable for toxicity will be replaced.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>Length of study</time_frame>
    <description>The MTD will be that dose at which fewer than one-third of patients experience DLT</description>
  </secondary_outcome>
  <enrollment type="Actual">33</enrollment>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed disodium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed solid tumor for which there is no known curative therapy or&#xD;
             therapy that is known to prolong survival with acceptable quality of life&#xD;
&#xD;
               -  Histologic requirement waived for intrinsic brain stem tumors&#xD;
&#xD;
          -  No pleural effusion or ascites&#xD;
&#xD;
          -  Neurological deficits from CNS tumors must have been relatively stable for at least 1&#xD;
             week prior to study entry&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  1 to 21&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 50-100% (over 10 years of age)&#xD;
&#xD;
          -  Lansky 50-100% (10 years of age and under)&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 8 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3 (transfusion independent)&#xD;
&#xD;
          -  Hemoglobin at least 8.0 g/dL (transfusion allowed)&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT no greater than 2.5 times ULN&#xD;
&#xD;
          -  Albumin at least 2 g/dL&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min OR&#xD;
&#xD;
          -  Creatinine based on age as follows:&#xD;
&#xD;
               -  No greater than 0.8 mg/dL (age 5 and under)&#xD;
&#xD;
               -  No greater than 1.0 mg/dL (age 6 to 10)&#xD;
&#xD;
               -  No greater than 1.2 mg/dL (age 11 to 15)&#xD;
&#xD;
               -  No greater than 1.5 mg/dL (age 16 and over)&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No evidence of dyspnea at rest&#xD;
&#xD;
          -  No exercise intolerance&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No evidence of Approved-not yet active graft-versus-host disease&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  Seizure disorder allowed provided it is well-controlled with anticonvulsants&#xD;
&#xD;
          -  CNS toxicity no greater than grade 1&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Recovered from prior immunotherapy&#xD;
&#xD;
          -  At least 7 days since prior antineoplastic biologic therapy&#xD;
&#xD;
          -  At least 6 months since prior allogeneic stem cell transplantation&#xD;
&#xD;
          -  More than 1 week since prior growth factors&#xD;
&#xD;
          -  No concurrent biologic therapy&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
          -  No concurrent prophylactic growth factor support during course 1&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior pemetrexed disodium&#xD;
&#xD;
          -  More than 3 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas)&#xD;
             and recovered&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Concurrent dexamethasone for CNS tumors allowed provided dose has been stable or&#xD;
             decreasing for at least 1 week prior to study entry&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Recovered from all prior radiotherapy&#xD;
&#xD;
          -  At least 2 weeks since prior local palliative radiotherapy&#xD;
&#xD;
          -  At least 6 months since prior craniospinal radiotherapy&#xD;
&#xD;
          -  At least 6 months since prior radiotherapy to 50% or more of the pelvis&#xD;
&#xD;
          -  At least 6 weeks since prior substantial bone marrow radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No trimethoprim or sulfa within 2 days before and after study drug administration&#xD;
&#xD;
          -  No concurrent nonsteroidal anti-inflammatory agents (e.g., ibuprofen and aspirin)&#xD;
&#xD;
          -  No other concurrent anticancer or investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H. Stacy Nicholson, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Linda C. Stork, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Doernbecher Children's Hospital at Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>323669</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center at Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5289</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NCI - Pediatric Oncology Branch</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>301496</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairview University Medical Center - University Campus</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216-4505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center at Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University Hospital</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute at Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>215590</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center - Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>832822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Regional Medical Center - Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>206987</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Sainte Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Malempati S, Nicholson HS, Reid JM, Blaney SM, Ingle AM, Krailo M, Stork LC, Melemed AS, McGovern R, Safgren S, Ames MM, Adamson PC; Children's Oncology Group. Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group. J Clin Oncol. 2007 Apr 20;25(12):1505-11. Erratum in: J Clin Oncol. 2008 Jan 1;26(1):165.</citation>
    <PMID>17442992</PMID>
  </results_reference>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>October 3, 2003</study_first_submitted>
  <study_first_submitted_qc>October 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2003</study_first_posted>
  <last_update_submitted>February 19, 2014</last_update_submitted>
  <last_update_submitted_qc>February 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

